Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations.
Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodríguez-Barrios F, d'Arrigo R, Ciccozzi M, Bertoli A, d'Arminio Monforte A, Balzarini J, Antinori A, Perno CF. Ceccherini-Silberstein F, et al. J Virol. 2005 Aug;79(16):10718-29. doi: 10.1128/JVI.79.16.10718-10729.2005. J Virol. 2005. PMID: 16051864 Free PMC article.
Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs.
Alteri C, Svicher V, Gori C, D'Arrigo R, Ciccozzi M, Ceccherini-Silberstein F, Selleri M, Bardacci SA, Giuliani M, Elia P, Scognamiglio P, Balzano R, Orchi N, Girardi E, Perno CF; SENDIH Study Group. Alteri C, et al. BMC Infect Dis. 2009 Jul 16;9:111. doi: 10.1186/1471-2334-9-111. BMC Infect Dis. 2009. PMID: 19607681 Free PMC article.
Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
Tozzi V, Zaccarelli M, Narciso P, Trotta MP, Ceccherini-Silberstein F, De Longis P, D'Offizi G, Forbici F, D'Arrigo R, Boumis E, Bellagamba R, Bonfigli S, Carvelli C, Antinori A, Perno CF. Tozzi V, et al. J Infect Dis. 2004 May 1;189(9):1688-95. doi: 10.1086/382960. Epub 2004 Apr 13. J Infect Dis. 2004. PMID: 15116307 Clinical Trial.
Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir.
Trotta MP, Bonfigli S, Ceccherini-Silberstein F, Bellagamba R, D'Arrigo R, Soldani F, Zaccarelli M, Concetta Bellocchi M, Lorenzini P, Marconi P, Boumis E, Forbici F, Comandini UV, Tozzi V, Narciso P, Federico Perno C, Antinori A. Trotta MP, et al. J Med Virol. 2006 May;78(5):535-41. doi: 10.1002/jmv.20573. J Med Virol. 2006. PMID: 16555278
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
Aquaro S, D'Arrigo R, Svicher V, Perri GD, Caputo SL, Visco-Comandini U, Santoro M, Bertoli A, Mazzotta F, Bonora S, Tozzi V, Bellagamba R, Zaccarelli M, Narciso P, Antinori A, Perno CF. Aquaro S, et al. J Antimicrob Chemother. 2006 Oct;58(4):714-22. doi: 10.1093/jac/dkl306. Epub 2006 Aug 5. J Antimicrob Chemother. 2006. PMID: 16891628
71 results